‘Priming’ the immune system with nivolumab (N) prior to tumour-directed therapy for the first line treatment of follicular lymphoma could potentially provide an alternative to chemotherapy, with the regimen demonstrating favourable toxicity and outcomes, according to research from Australia presented at ASCO this week. In a poster session, oncologist and lymphoma lead clinal scientist at ...
ASCO 21: Associate Professor Eliza Hawkes on nivolumab ‘priming’ in FL
By Sunalie Silva
10 Jun 2021